Advanced search
Publication Cover
Personalized Medicine Volume 12, 2015 - Issue 2
Submit an article Journal homepage
764
Views
0
CrossRef citations to date
0
Altmetric
Editorial

The Birth and Potential Death of Il28B Genotyping for Hepatitis C Therapy

Alan HB Wua Department of Laboratory Medicine, University of California, San Francisco, CA 94143, USACorrespondence[email protected]
&
Mandana Khalilib Department of Clinical Medicine, University of California, San Francisco, CA 94143, USA
Pages 55-57 | Published online: 23 Mar 2015

References

  • Armstrong LG , WasleyA , SimardEPet al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 . Ann. Intern. Med.144 ( 10 ), 705 – 714 ( 2006 ).
  • Perz JF , ArmstrongGL , FarringtonLAet al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide . J. Hepatol.45 ( 4 ), 529 – 358 ( 2006 ).
  • Ghany MG , StraderDB , ThomasDLet al. Diagnosis, management, and treatment of hepatitis C: an update . Hepatology49 ( 4 ), 1335 – 1374 ( 2009 ).
  • Smith BD , MorganRL , BeckettGAet al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965 . MMWR Recomm. Rep.61 ( RR04 ), 1 – 32 ( 2012 ).
  • Ghany MG , LiangTJ . Current and future therapies for hepatitis C virus infection . N. Engl. J. Med.369 ( 7 ), 679 – 680 ( 2013 ).
  • Manns MP , McHutchinsonJG , GordonSCet al. Peginteferon alfa-2b plus ribavirin compared with interferon alfa-2b plus rivavirin for initial treatment of chronic hepatitis C: a randomized trial . Lancet358 ( 9286 ), 958 – 965 ( 2001 ).
  • Ge D , FellayJ , ThompsonAJet al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance . Nature461 ( 17 ), 399 – 401 ( 2009 ).
  • Tanaka Y , NishidaN , SugiyamaMet al. Genome-wide association of IL28B with response to pegylated interferon-alpha and rivavirin therapy for chronic hepatitis C . Nat. Genet.41 , 1105 – 1109 ( 2009 ).
  • Clark PJ , ThompsonAJV , McHutchisonJG . Genetic variation in IL28B: impact on drug development for chronic hepatitis C infection . Clin. Pharmacol. Therap.88 ( 5 ), 708 – 711 ( 2010 ).
  • Fischer J , BohmS , ScholzMet al. Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection . Hepatology55 ( 6 ), 1700 – 1710 ( 2012 ).
  • Thompson AJ , FellayJ , PatelKet al. Variants in the ITA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction . Gastroenterology139 , 1181 – 1191 ( 2010 ).
  • Zeuzem S , AndreoneP , PolSet al. Telaprevir for retreatment of HCV infection . N. Engl. J. Med.364 ( 25 ), 2417 – 2427 ( 2011 ).
  • Poordad F , McConeJJr , BaconBret al. Boceprevir for untreated chronic HCV genotype 1 infection . N. Engl. J. Med.364 ( 13 ), 1195 – 1206 ( 2011 ).
  • Liu S , CiprianoLE , HolodniyMet al. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis . Ann. Intern. Med.156 ( 4 ), 279 – 290 ( 2012 ).
  • Jacobson IM , DoreGJ , FosterGRet al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial . Lancet384 ( 9941 ), 403 – 413 ( 2014 ).
  • Lawitz E , MangiaA , WylesDet al. Sofosbuvir for previously untreated chronic hepatitis C infection . N. Engl. J. Med.368 ( 20 ), 1878 – 1887 ( 2013 ).
  • Zuezum S , DusheikoGM , SalupereRet al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3 . N. Engl. J. Med.370 ( 21 ), 1993 – 2001 ( 2014 ).
  • Recommendations for testing, managing, and treating hepatitis C . American association for the study of liver diseases . www.hcvguidelines.org/full-report-view .
  • Petta S , CabibboG , EneaMet al. Cost-effective of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C . Hepatology59 , 1692 – 1705 ( 2014 ).
  • Ferenci P , BernsteinD , LalezariJet al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV . N. Engl. J. Med.370 , 1893 – 1991 ( 2014 ).
  • Feld JJ , LowdleyKV , CoakleyEet al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin . N. Engl. J. Med.370 ( 17 ), 1594 – 1603 ( 2014 ).
  • Afdhal N , ZeuzemS , KwoPet al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection . N. Engl. J. Med.370 ( 20 ), 1889 – 1898 ( 2014 ).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.